Our Proprietary Technology Platforms
Our two unique proprietary and versatile
technology platforms are engines to drive the growth of our development: our SupraAntigen platform, which is our biological and
immunological platform, and our Morphomer platform, which is our small molecule, chemical platform. These platforms are designed
to generate vaccines, antibodies and small molecules, respectively, which selectively interact with misfolded proteins that are
common in a broad range of neurodegenerative diseases.
Our SupraAntigen platform generates humanized
monoclonal antibodies and vaccines for use as passive and active immunotherapies that are highly specific for pathological, or
misfolded, forms of proteins typically found in neurodegenerative diseases.
The key advantages of the SupraAntigen
|·||Highly selective conformation-specific immunotherapy;|
|·||Generation of antibodies and vaccines;|
|·||Generation of a rapid antibody response; and|
|·||Favorable safety avoiding T-cell mediated inflammation.|
Product candidates generated utilizing
the SupraAntigen platform include crenezumab in Phase 2 in AD, ACI-24 in Phase 2 in AD and Phase 1b in DS, ACI-35 in Phase 1b in
AD, an anti-Tau antibody in Phase 2 in AD and the pre-clinical antibodies for alpha-synuclein/TDP-43 in PD and neuro-orphan indications.
Our Morphomer platform represents a highly
promising technology that enables us to generate conformation specific small molecules through rational design. As of December 31,
2018, our Morphomer library consisted of more than 4,750 compounds. This proprietary platform enables us to generate small molecules
that bind to their target and break up neurotoxic protein aggregates or act as propagation inhibitors.
Therapeutic product candidates generated
by the Morphomer platform include the pre-clinical therapeutic programs such as Morphomer Tau in AD, Morphomer alpha-synuclein
in PD and the diagnostic programs Tau-PET imaging agent in Phase 1 in AD and PSP and alpha-synuclein-PET and TDP-43 PET imaging
agents in the pre-clinical stage.
Our AD Programs
Crenezumab is a humanized, conformation-specific
monoclonal antibody that targets misfolded Abeta and has a broad binding profile. Crenezumab was developed using our proprietary
SupraAntigen platform. In 2006, we licensed crenezumab to Genentech, a company with a long history of developing and commercializing